Health Signal — https://economictimes.indiatimes.com/industry/healthcare/bio — OpenWatch

Real-time global intelligence

© 2026 OpenWatch. All rights reserved.

Proudly using no third-party tracking

Illustrative, not investment advice. OpenWatch aggregates public signals for research and information only — it is not personalized financial, legal, or tax advice, and nothing here is a recommendation to buy or sell any security.

Platform

Brief
Signals
Cascade
Trajectories
Wagers
Track Record
Countries
Companies
Industries
Themes
Rankings

Tools

Globe
Analytics
Crises
Clusters
Supply Chain
Alliances
Screener
Watchlist
Portfolio

Developer

Status

Sources

View all sources →

1,000+ tracked sources

Signals updated every 15 minutes

Not investment advice. OpenWatch is provided for informational and entertainment purposes only. While we strive for accuracy, precision, and source attribution in all intelligence assessments, geopolitical analysis involves inherent uncertainty and our conclusions may be incomplete, delayed, or incorrect. Nothing on this platform constitutes financial, investment, legal, or professional advice of any kind. Forward-looking scenarios and probability estimates are analytical hypotheses — not independently validated forecasts. Any actions taken based on information found here are solely your responsibility. Always consult a qualified financial advisor before making investment decisions. Past signal patterns do not guarantee future outcomes.

Methodology
Privacy Policy
Terms of Use

openwatch.io

v·a0cf629

← Back to search

HealthupdateUSA 🇮🇳IndiaJune 9, 2026

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indias-anti-obesity-drug-market-sees-slower-growth-after-initial-surge-in-generic-semaglutide-sales/articleshow/131596242.cms

Severity: 3.1/10Source: GDELT 2.0 Master Files

Read full report ↗Related signals →

Health Signal — https://economictimes.indiatimes.com/industry/healthcare/bio — OpenWatch